sialic acid

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: sialic acid
• 英文别名: N-Acetyl-D-neuraminsaeure；N-Acetylneuraminsaeure；(4S,5R,6R)-5-acetamido-2,4-dihydroxy-6-(1,2,3-trihydroxypropyl)oxane-2-carboxylic acid
• 化学式: C₁₁H₁₉NO₉
• 分子量: 309.273
• InChiKey: SQVRNKJHWKZAKO-QCYZDSGZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.5
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  177
• 氢给体数：
  7
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  sialic acid 、 十八胺 在 N-羟基丁二酰亚胺 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 生成
  参考文献：
  名称：

  Sequential administration of sialic acid-modified liposomes as carriers for epirubicin and zoledronate elicit stronger antitumor effects with reduced toxicity

  摘要：

  DOI：

  10.1016/j.ijpharm.2021.120552

文献信息

• [EN] VIRUCIDAL COMPOSITIONS AND USE THEREOF<br/>[FR] COMPOSITIONS VIROCIDES ET LEUR UTILISATION
  申请人：ECOLE POLYTECHNIQUE FED LAUSANNE EPFL

  公开号：WO2021198139A1

  公开（公告）日：2021-10-07

  The invention relates to virucidal compositions comprising a sialic acid (SA) moiety, pharmaceutical compositions and disinfection and/or sterilization compositions comprising thereof and uses thereof in disinfection and/or sterilization methods and in treating and/or preventing COVID-19 and other respiratory diseases caused by coronaviruses and/or influenza viruses.

  该发明涉及含有唾液酸（SA）基团的灭病毒组合物，包括其中的药物组合物和消毒/灭菌组合物，以及在消毒/灭菌方法中使用它们以及在治疗和/或预防由冠状病毒和/或流感病毒引起的COVID-19和其他呼吸道疾病中的用途。
• [EN] PREPARATION OF SUGAR-NUCLEOTIDES<br/>[FR] PRÉPARATION DE SUCRES-NUCLÉOTIDES
  申请人：NOVO NORDISK AS

  公开号：WO2018115309A1

  公开（公告）日：2018-06-28

  The present invention relates to methods for preparation of glyco-conjugated proteins and in particular to processes for preparation of sugar-nucleotides and modified sugar-nucleotides.

  本发明涉及制备糖基结合蛋白质的方法，特别是制备糖核苷酸和修饰糖核苷酸的过程。
• ANTI-LAP ANTIBODY VARIANTS AND USES THEREOF
  申请人：Tilos Theapeutics, Inc.

  公开号：EP3863722A2

  公开（公告）日：2021-08-18
• METHODS FOR SPATIAL ANALYSIS USING PROXIMITY LIGATION
  申请人：10x Genomics, Inc.

  公开号：US20210230681A1

  公开（公告）日：2021-07-29

  The present disclosure provides methods and compositions for detecting and spatially locating analyte interactions and gene expression in a biological sample. For example, provided herein are methods of determining a location of at least one analyte in a biological sample using analyte-binding moieties, proximity ligation, and an array including capture probes.
• ANUCLEATED CELLS FOR THE TREATMENT OF DISEASES
  申请人：Platelet Biogenesis, Inc.

  公开号：US20210299181A1

  公开（公告）日：2021-09-30

  The present disclosure takes advantage of non-naturally existing, novel, anucleated platelets or platelet-like cells or platelet variants (collectively referred to as PLCs) or derivatives thereof (i.e., genetically engineered), which share at least one common receptor, ligand or an antigen with endogenous cells that are targets for autoantibodies and effectuate their clearance. The present disclosure also takes advantage of viral adhesion or entry receptors or genetically engineered PLCs or derivatives thereof, which are engineered to express viral adhesion or entry receptors, that specifically binds to viral proteins on viruses or viral particles and effectuate their clearance.